Viral Vector Services

Vectors that go from 0-QP release in 6 months

 
 

A viral vector CDMO powered by innovation

 
 

Our specialized viral vector services help bring therapeutic programs to life by translating lentiviral and retroviral-based therapies from idea to reality.

  • Our Innovation Research team is developing next-generation vector platforms to support industry evolution, ensuring we remain at the forefront of lentiviral vector science.

  • Team ViroCell leverages decades of viral vector research and clinical outcome analysis to develop robust lentiviral and retroviral vector design strategies that de-risk your program. We consider productive titers and clinical objectives from the start.

  • High-yield platform process developed by team of deeply committed scientists with unparalleled technical expertise, with 20+ years of experience and ~200 GMP batches manufactured.

  • Agile and cost-efficient GMP manufacturing services meet critical early phase needs, high titer, rapid delivery (6 months from plasmid to GMP batch release), and phase appropriate quality.

 

Our viral vector services

 

Innovation Research

Driven to improve yields and enhance vector function

Viral Vector Design & Optimization

Experience in complex vector design and optimization

Viral Vector Process Development

Process optimization and preclinical manufacturing

GMP Manufacturing

Lentiviral and retroviral GMP manufacturing platform process

Regulatory Submissions

IND, IMPD, CTA, MHRA, FDA and EMA support

 
“We’ve designed a plug-and-play approach so that we can deliver a vector to clients within six months of starting their manufacturing campaign.”
— JOHN W. HADDEN II, CHIEF EXECUTIVE OFFICER

Innovative thinking: Articles

De-risking cell and gene therapies by leveraging a proven workhorse technology in new ways

July 2025

Team ViroCell believes that innovation doesn’t always require new discoveries. Sometimes, it’s about combining proven elements... Read the article.